In the future, the clinical significance of EGFR mutations detected in plasma at early-stage should be studied, and may be particularly valuable in clarifying the connection between EGFR mutations in plasma and the risk of tumor relapse, especially considering tumor EGFR mutation status-associated EGFR protein expression is a significant risk factor for tumor relapse in early-stage NSCLC [14,15]. This evidence concerns the gene EGFR and neoplasm.